HHS has decided to formalize its “penny pricing” policy for prescription drugs sold at 340B discounts despite arguments from manufacturers that alternatives allowing for higher prices should be adopted.
“After consideration of the comments received, HHS is finalizing the penny pricing policy as proposed,” according to a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?